Bausch Health Companies Inc. income statement
In fiscal 2025, Bausch Health Companies Inc. reported revenue of $10.27bn, up 6.7% on the year before, operating income of $1.81bn (a 17.7% margin) and net income of $157m, or $0.42 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.8 | 1.2 | 2.4 | 3.5 | 5.8 | 8.2 | 10.4 | 9.7 | 8.7 | 8.4 | 8.6 | 8.0 | 8.4 | 8.1 | 8.8 | 9.6 | 10.3 | 11.1 |
| Research and development | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 |
| Selling, general and administrative | 0.2 | 0.3 | 0.6 | 0.8 | 1.3 | 2.0 | 2.7 | 2.8 | 2.6 | 2.5 | 2.6 | 2.4 | 2.6 | 2.6 | 2.9 | 3.3 | 3.4 | 3.5 |
| Operating income | 0.2 | −0.1 | 0.3 | 0.1 | −0.4 | 2.0 | 1.5 | −0.6 | 0.1 | −2.4 | −0.2 | 0.7 | 0.5 | 0.5 | 1.0 | 1.5 | 1.8 | 1.2 |
| Interest expense | — | — | — | — | — | — | — | — | 1.8 | 1.7 | 1.6 | 1.5 | 1.4 | 1.5 | 1.3 | 1.4 | 1.6 | 1.6 |
| Income before tax | 0.2 | −0.2 | −0.0 | −0.4 | −1.3 | 1.1 | −0.2 | −2.4 | −1.7 | −4.2 | −1.8 | −0.9 | −1.0 | −0.1 | −0.4 | 0.2 | 0.4 | −0.4 |
| Income tax | −0.0 | −0.0 | −0.2 | −0.3 | −0.5 | 0.2 | 0.1 | −0.0 | −4.1 | −0.0 | −0.1 | −0.4 | −0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.5 |
| Net income | 0.2 | −0.2 | 0.2 | −0.1 | −0.9 | 0.9 | −0.3 | −2.4 | 2.4 | −4.1 | −1.8 | −0.6 | −0.9 | −0.2 | −0.6 | −0.0 | 0.2 | −0.8 |
| Diluted EPS | $1.11 | −$1.06 | $0.49 | −$0.38 | −$2.70 | $2.58 | −$0.85 | −$6.94 | $6.83 | −$11.81 | −$5.08 | −$1.58 | −$2.64 | −$0.62 | −$1.62 | −$0.13 | $0.42 | −$2.22 |
| Diluted shares (average) | 159m | 196m | 326m | 305m | 321m | 342m | 343m | 347m | 352m | 351m | 352m | 355m | 359m | 362m | 365m | 368m | 375m | 378m |
| EBITDA | 0.3 | 0.1 | 0.9 | 1.1 | 1.6 | 3.6 | 4.0 | 2.3 | 3.0 | 0.4 | 1.9 | 2.5 | 2.0 | 1.8 | 2.2 | 2.8 | 3.0 | 2.4 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,559 | 2,259 | 2,530 | 2,681 | 2,796 | 2,524 | 2,852 | 2,941 |
| Research and development | 163 | 143 | 159 | 166 | 161 | 163 | 173 | 141 |
| Selling, general and administrative | 820 | 867 | 894 | 795 | 882 | 861 | 907 | 834 |
| Operating income | 558 | 276 | 444 | 619 | 474 | −950 | 740 | 983 |
| Interest expense | 337 | 330 | 465 | 412 | 397 | 402 | 396 | 398 |
| Income before tax | 209 | −47 | 140 | 218 | 56 | −1,354 | 348 | 597 |
| Income tax | 111 | 39 | 12 | 37 | 159 | 77 | 88 | 151 |
| Net income | 93 | −58 | 148 | 179 | −112 | −1,423 | 258 | 436 |
| Diluted EPS | $0.25 | −$0.16 | $0.40 | $0.48 | −$0.30 | −$3.82 | $0.68 | $1.15 |
| EBITDA | 865 | 581 | 751 | 925 | 764 | −655 | 1,021 | 1,267 |
Compare with peers
- Zoetis income statement
- Haleon plc income statement
- Viatris income statement
- Universe Pharmaceuticals Inc income statement
- Organon & Co. income statement
Head to head: BHC vs ZTSBHC vs HLNBHC vs VTRSBHC vs UPC
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies